{
    "hands_on_practices": [
        {
            "introduction": "Making informed off-label decisions often begins with a fundamental question: how much effect can we expect at a given dose? This exercise applies the classic $E_{max}$ model, a cornerstone of pharmacodynamics, to predict the clinical response to a therapy in a new population based on existing data. Mastering this skill  is essential for setting realistic expectations and designing appropriate dosing regimens when formal guidance is unavailable.",
            "id": "4569302",
            "problem": "A monoclonal antibody originally approved for adult autoimmune disease is being considered for off-label use to reduce C-reactive protein in pediatric Kawasaki disease. The pharmacodynamic endpoint is the mean reduction in C-reactive protein, expressed in milligrams per liter. Prior adult exposure-response analyses indicate a saturable, maximum-effect relationship between concentration and response that is consistent with receptor occupancy fundamentals, with a baseline effect of $E_{0}$ and a maximum achievable reduction of $E_{max}$. The half-maximal effective concentration $EC_{50}$ is uncertain due to inter-study variability.\n\nFor this off-label scenario, assume the following empirically supported and physiologically plausible parameters: baseline reduction $E_{0} = 0$ milligrams per liter, maximum reduction $E_{max} = 40$ milligrams per liter, and an estimated half-maximal effective concentration $EC_{50} = 8$ milligrams per liter, with an uncertainty characterized by a standard deviation of $2$ milligrams per liter from prior meta-analysis. Pediatric pharmacokinetic scaling predicts the proposed regimen will achieve a steady-state average concentration of $C = 12$ milligrams per liter.\n\nUsing a well-tested, saturable maximum-effect exposure-response framework grounded in receptor occupancy, compute the predicted mean reduction in C-reactive protein at the proposed exposure. Express your final answer in milligrams per liter and round your answer to four significant figures. In your reasoning, begin from receptor occupancy fundamentals and explain how uncertainty in $EC_{50}$ propagates to the predicted effect via a first-order approximation, but report only the predicted mean reduction as your final numerical answer.",
            "solution": "The problem requires the computation of a predicted mean reduction in C-reactive protein using a standard pharmacodynamic model. The validation of the problem statement is the first critical step.\n\nThe givens extracted from the problem statement are:\n- A saturable, maximum-effect ($E_{max}$) model describes the concentration-response relationship.\n- Baseline effect: $E_{0} = 0$ milligrams per liter.\n- Maximum achievable reduction: $E_{max} = 40$ milligrams per liter.\n- Mean half-maximal effective concentration: $\\mu_{EC_{50}} = 8$ milligrams per liter.\n- Standard deviation of the half-maximal effective concentration: $\\sigma_{EC_{50}} = 2$ milligrams per liter.\n- Steady-state average drug concentration: $C = 12$ milligrams per liter.\n\nThe problem is scientifically grounded, employing the well-established $E_{max}$ model which is based on receptor occupancy theory. All necessary parameters are provided, making the problem well-posed and self-contained. The values are physiologically plausible, and the language is objective and quantitative. Therefore, the problem is deemed valid and a solution can be formulated.\n\nThe saturable maximum-effect relationship between drug concentration ($C$) and the resulting pharmacological effect ($E$) is described by the sigmoidal $E_{max}$ model, which is a form of the Hill-Langmuir equation:\n$$E(C) = E_{0} + \\frac{E_{max} \\cdot C^n}{EC_{50}^n + C^n}$$\nThe problem describes a relationship consistent with fundamental receptor occupancy, which corresponds to a Hill coefficient ($n$) of $1$. The model thus simplifies to:\n$$E(C) = E_{0} + \\frac{E_{max} \\cdot C}{EC_{50} + C}$$\nIn this equation, $E(C)$ represents the effect (reduction in C-reactive protein) at a given drug concentration $C$. $E_{0}$ is the baseline effect at zero drug concentration, $E_{max}$ is the maximum possible effect, and $EC_{50}$ is the concentration required to achieve $50\\%$ of the maximum effect.\n\nThe problem asks for the \"predicted mean reduction\". This is interpreted as the point estimate of the effect calculated using the mean value of the uncertain parameter, $EC_{50}$. Substituting the provided values:\n$$E_{0} = 0 \\, \\text{mg/L}$$\n$$E_{max} = 40 \\, \\text{mg/L}$$\n$$C = 12 \\, \\text{mg/L}$$\n$$\\mu_{EC_{50}} = 8 \\, \\text{mg/L}$$\nThe predicted effect $E$ at the concentration $C=12$ mg/L is:\n$$E(12) = 0 + \\frac{40 \\cdot 12}{8 + 12} = \\frac{480}{20} = 24$$\nSo, the predicted mean reduction in C-reactive protein is $24$ mg/L.\n\nThe problem also requires an explanation of how uncertainty in $EC_{50}$ propagates to the predicted effect, using a first-order approximation. This is accomplished using the delta method to estimate the variance of the effect, $\\text{Var}(E)$. We treat the effect $E$ as a function of the random variable $EC_{50}$.\n$$E(EC_{50}) = \\frac{E_{max} \\cdot C}{EC_{50} + C}$$\nThe first-order Taylor series approximation for the variance of $E$ is:\n$$\\text{Var}(E) \\approx \\left( \\frac{dE}{d(EC_{50})} \\bigg|_{\\mu_{EC_{50}}} \\right)^2 \\text{Var}(EC_{50})$$\nwhere $\\text{Var}(EC_{50}) = \\sigma_{EC_{50}}^2$.\n\nFirst, we must find the derivative of $E$ with respect to $EC_{50}$:\n$$\\frac{dE}{d(EC_{50})} = \\frac{d}{d(EC_{50})} \\left( (E_{max} \\cdot C) \\cdot (EC_{50} + C)^{-1} \\right) = - \\frac{E_{max} \\cdot C}{(EC_{50} + C)^2}$$\nNext, we evaluate this derivative at the mean value $\\mu_{EC_{50}} = 8$ mg/L:\n$$\\frac{dE}{d(EC_{50})} \\bigg|_{\\mu_{EC_{50}}=8} = - \\frac{40 \\cdot 12}{(8 + 12)^2} = - \\frac{480}{20^2} = - \\frac{480}{400} = -1.2$$\nThis derivative is a unitless sensitivity coefficient. The variance of $EC_{50}$ is given by:\n$$\\text{Var}(EC_{50}) = \\sigma_{EC_{50}}^2 = (2 \\, \\text{mg/L})^2 = 4 \\, (\\text{mg/L})^2$$\nNow, we can approximate the variance of the effect:\n$$\\text{Var}(E) \\approx (-1.2)^2 \\cdot 4 \\, (\\text{mg/L})^2 = 1.44 \\cdot 4 \\, (\\text{mg/L})^2 = 5.76 \\, (\\text{mg/L})^2$$\nThe corresponding standard deviation of the effect is $\\sigma_E = \\sqrt{5.76} \\, \\text{mg/L} = 2.4 \\, \\text{mg/L}$. This quantifies the uncertainty in the predicted effect due to the uncertainty in $EC_{50}$.\n\nWhile the uncertainty analysis provides important context, the question asks for the numerical value of the predicted mean reduction. Based on our calculation, this value is $24$ mg/L. The problem specifies rounding to four significant figures, which yields $24.00$.",
            "answer": "$$\\boxed{24.00}$$"
        },
        {
            "introduction": "Effective off-label practice requires not only predicting efficacy but also clearly communicating the balance of benefits and harms. This practice will guide you through the process of translating statistical measures like relative risk into clinically intuitive metrics such as the Number Needed to Treat (NNT) and Number Needed to Harm (NNH). By working through this scenario , you will develop the quantitative skills needed to assess the net impact of a therapy, accounting for real-world complexities like patient adherence.",
            "id": "4569317",
            "problem": "An off-label prescribing decision in clinical pharmacology requires transparent risk communication. Consider an off-label prophylactic use of a drug intended to reduce an undesirable clinical event over a $1$-month horizon. For a specific patient, the estimated baseline risk of the undesirable clinical event without treatment is $0.30$. A meta-analysis reports that, among adherent patients, the drug yields a relative risk of the undesirable clinical event of $0.70$ compared with no treatment. The drug can also cause a serious adverse event; the patientâ€™s baseline risk of this adverse event without treatment is $0.05$, and among adherent patients the relative risk of this adverse event with the drug is $1.80$. In real-world use, only a fraction $a=0.80$ of patients are adherent over the $1$-month horizon; assume that non-adherent patients experience the baseline risks unchanged, while adherent patients experience the relative-risk-modified risks.\n\nStarting only from the core definitions of risk, relative risk, absolute risk reduction, absolute risk increase, Number Needed to Treat (NNT), and Number Needed to Harm (NNH), translate the relative risks into absolute risks for this patient under the adherence assumption, compute the absolute risk reduction for benefit and the absolute risk increase for harm, and then compute NNT and NNH. Finally, compute the help-to-harm ratio defined as $\\text{NNH}/\\text{NNT}$ for this patient under real-world adherence.\n\nExpress the final ratio as a dimensionless number rounded to four significant figures. Do not include any units in your final answer.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n- Baseline risk of the undesirable clinical event (control group risk for benefit): $R_{\\text{event, baseline}} = 0.30$\n- Relative risk of the undesirable clinical event with treatment (for adherent patients): $RR_{\\text{event}} = 0.70$\n- Baseline risk of the serious adverse event (control group risk for harm): $R_{\\text{harm, baseline}} = 0.05$\n- Relative risk of the serious adverse event with treatment (for adherent patients): $RR_{\\text{harm}} = 1.80$\n- Fraction of patients who are adherent: $a = 0.80$\n- Assumption for non-adherent patients: they experience baseline risks for both the undesirable event and the adverse event.\n- Assumption for adherent patients: they experience risks modified by the respective relative risks.\n- The time horizon is $1$ month.\n- The task is to compute the help-to-harm ratio, defined as $\\frac{\\text{NNH}}{\\text{NNT}}$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem uses standard, well-defined concepts from clinical epidemiology and pharmacology, such as risk, relative risk, NNT (Number Needed to Treat), and NNH (Number Needed to Harm). The numerical values are plausible.\n- **Well-Posed:** All necessary data and assumptions are provided to calculate the requested ratio. The question is structured to guide a unique and meaningful solution.\n- **Objective:** The problem is stated in precise, quantitative terms, free from subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A complete solution is provided below.\n\n### Solution Derivation\nThe solution will be developed by following the steps outlined in the problem statement, starting from the core definitions.\n\nLet us define the primary parameters and events:\n- $E$: The undesirable clinical event (the 'benefit' is avoiding this event).\n- $H$: The serious adverse event (the 'harm').\n- $R_{\\text{event, baseline}}$: The baseline risk of event $E$, $P(E | \\text{No Treatment}) = 0.30$.\n- $R_{\\text{harm, baseline}}$: The baseline risk of event $H$, $P(H | \\text{No Treatment}) = 0.05$.\n- $RR_{\\text{event}}$: The relative risk for event $E$ in adherent patients, $RR_{\\text{event}} = 0.70$.\n- $RR_{\\text{harm}}$: The relative risk for event $H$ in adherent patients, $RR_{\\text{harm}} = 1.80$.\n- $a$: The fraction of adherent patients, $a = 0.80$. The fraction of non-adherent patients is $1-a = 0.20$.\n\nThe core definitions are as follows:\n- **Risk** is the probability of an event in a defined population over a specific time.\n- **Relative Risk ($RR$)** is the ratio of the risk in the treated group to the risk in the control group.\n- **Absolute Risk Reduction ($ARR$)** for a beneficial outcome is $R_{\\text{control}} - R_{\\text{treatment}}$.\n- **Absolute Risk Increase ($ARI$)** for a harmful outcome is $R_{\\text{treatment}} - R_{\\text{control}}$.\n- **Number Needed to Treat ($NNT$)** is the reciprocal of the $ARR$, so $NNT = \\frac{1}{ARR}$.\n- **Number Needed to Harm ($NNH$)** is the reciprocal of the $ARI$, so $NNH = \\frac{1}{ARI}$.\n\n**1. Translate Relative Risks into Absolute Risks under Adherence**\n\nFirst, we calculate the absolute risks for the two subgroups within the treated population: adherent and non-adherent patients.\n\nFor the undesirable clinical event ($E$):\n- Risk for an adherent patient: $R_{\\text{event, adherent}} = R_{\\text{event, baseline}} \\times RR_{\\text{event}} = 0.30 \\times 0.70 = 0.21$.\n- Risk for a non-adherent patient: $R_{\\text{event, non-adherent}} = R_{\\text{event, baseline}} = 0.30$.\n\nFor the serious adverse event ($H$):\n- Risk for an adherent patient: $R_{\\text{harm, adherent}} = R_{\\text{harm, baseline}} \\times RR_{\\text{harm}} = 0.05 \\times 1.80 = 0.09$.\n- Risk for a non-adherent patient: $R_{\\text{harm, non-adherent}} = R_{\\text{harm, baseline}} = 0.05$.\n\n**2. Calculate Overall Risk in the Treated Population**\n\nThe overall risk in the real-world treated population is the weighted average of the risks in the adherent and non-adherent subgroups, where the weights are the proportions of each subgroup. This is an application of the law of total probability.\n\nOverall risk of the undesirable clinical event with treatment ($R_{\\text{event, treat}}$):\n$$R_{\\text{event, treat}} = (R_{\\text{event, adherent}} \\times a) + (R_{\\text{event, non-adherent}} \\times (1-a))$$\n$$R_{\\text{event, treat}} = (0.21 \\times 0.80) + (0.30 \\times 0.20) = 0.168 + 0.060 = 0.228$$\n\nOverall risk of the serious adverse event with treatment ($R_{\\text{harm, treat}}$):\n$$R_{\\text{harm, treat}} = (R_{\\text{harm, adherent}} \\times a) + (R_{\\text{harm, non-adherent}} \\times (1-a))$$\n$$R_{\\text{harm, treat}} = (0.09 \\times 0.80) + (0.05 \\times 0.20) = 0.072 + 0.010 = 0.082$$\n\n**3. Compute Absolute Risk Reduction (ARR) for Benefit**\n\nThe $ARR$ is the difference between the risk of the undesirable event without treatment and with treatment.\n$$ARR = R_{\\text{event, baseline}} - R_{\\text{event, treat}}$$\n$$ARR = 0.30 - 0.228 = 0.072$$\n\n**4. Compute Absolute Risk Increase (ARI) for Harm**\n\nThe $ARI$ is the difference between the risk of the adverse event with treatment and without treatment.\n$$ARI = R_{\\text{harm, treat}} - R_{\\text{harm, baseline}}$$\n$$ARI = 0.082 - 0.05 = 0.032$$\n\n**5. Compute NNT and NNH**\n\nUsing the definitions, we can now find $NNT$ and $NNH$.\n$$NNT = \\frac{1}{ARR} = \\frac{1}{0.072}$$\n$$NNH = \\frac{1}{ARI} = \\frac{1}{0.032}$$\n\n**6. Compute the Help-to-Harm Ratio**\n\nThe final step is to compute the ratio $\\frac{\\text{NNH}}{\\text{NNT}}$.\n$$\\frac{\\text{NNH}}{\\text{NNT}} = \\frac{1/ARI}{1/ARR} = \\frac{ARR}{ARI}$$\nSubstituting the calculated values for $ARR$ and $ARI$:\n$$\\frac{\\text{NNH}}{\\text{NNT}} = \\frac{0.072}{0.032} = \\frac{72}{32} = \\frac{9}{4} = 2.25$$\n\nThe problem requires the answer to be rounded to four significant figures.\n$$2.25 = 2.250$$\n\nIt is instructive to note that the ratio can be expressed symbolically.\n$$ARR = R_{\\text{event, baseline}} - [ (R_{\\text{event, baseline}} \\times RR_{\\text{event}})a + R_{\\text{event, baseline}}(1-a) ] = R_{\\text{event, baseline}} [1 - (a \\cdot RR_{\\text{event}} + 1 - a)] = R_{\\text{event, baseline}} \\cdot a \\cdot (1 - RR_{\\text{event}})$$\n$$ARI = [ (R_{\\text{harm, baseline}} \\times RR_{\\text{harm}})a + R_{\\text{harm, baseline}}(1-a) ] - R_{\\text{harm, baseline}} = R_{\\text{harm, baseline}} [ (a \\cdot RR_{\\text{harm}} + 1 - a) - 1 ] = R_{\\text{harm, baseline}} \\cdot a \\cdot (RR_{\\text{harm}} - 1)$$\nThus, the ratio is:\n$$\\frac{\\text{NNH}}{\\text{NNT}} = \\frac{ARR}{ARI} = \\frac{R_{\\text{event, baseline}} \\cdot a \\cdot (1 - RR_{\\text{event}})}{R_{\\text{harm, baseline}} \\cdot a \\cdot (RR_{\\text{harm}} - 1)} = \\frac{R_{\\text{event, baseline}} (1 - RR_{\\text{event}})}{R_{\\text{harm, baseline}} (RR_{\\text{harm}} - 1)}$$\nThis demonstrates that under the stated assumptions, the help-to-harm ratio is independent of the adherence rate $a$.\nUsing this formula:\n$$\\frac{\\text{NNH}}{\\text{NNT}} = \\frac{0.30 \\times (1 - 0.70)}{0.05 \\times (1.80 - 1)} = \\frac{0.30 \\times 0.30}{0.05 \\times 0.80} = \\frac{0.09}{0.04} = 2.25$$\nThe result is consistent.",
            "answer": "$$\\boxed{2.250}$$"
        },
        {
            "introduction": "Real-world clinical decisions are rarely based on a single metric; they involve a complex trade-off between efficacy, safety, feasibility, and quality of life. This final exercise introduces Multi-Criteria Decision Analysis (MCDA) as a structured framework for systematically evaluating and comparing treatment options across multiple dimensions. By performing a sensitivity analysis , you will learn how to make a robust and transparent choice, even when stakeholder priorities and evidence are uncertain.",
            "id": "4569304",
            "problem": "A clinician at an academic medical center is evaluating two off-label pharmacotherapies for chemotherapy-induced peripheral neuropathic pain in adult cancer survivors. The decision must explicitly integrate considerations unique to off-label use: absence of regulatory approval for the indication, variability in evidence quality, and ethical prioritization of benefit-risk profiles under uncertainty. The evaluation will use Multi-Criteria Decision Analysis (MCDA), defined here as a structured decision framework that aggregates normalized criterion-specific values under a linear additive value model with nonnegative weights that sum to $1$, and linear transformations mapping raw criterion measures to $[0,1]$ where $1$ is most preferred and $0$ is least preferred.\n\nTwo alternatives, Drug $A$ and Drug $B$, are characterized across four criteria: efficacy, safety, quality of life, and feasibility. The data are as follows, each aligned to a clinically plausible, well-tested measurement scale for off-label consideration:\n\n- Efficacy: absolute response rate increase (risk difference) versus usual care, given as $0.18$ for Drug $A$ and $0.11$ for Drug $B$. Normalize linearly on $[0,1]$ over the range $[0,0.35]$, where higher is better.\n- Safety: proportion of patients with Grade $3$-$4$ adverse events, given as $0.17$ for Drug $A$ and $0.10$ for Drug $B$. Normalize linearly on $[0,1]$ over the range $[0.05,0.25]$, where lower is better.\n- Quality of Life (QoL): improvement on a validated $0$ to $100$ scale measured as change from baseline in the pain interference subscale, given as $12$ points for Drug $A$ and $8$ points for Drug $B$. Normalize linearly on $[0,1]$ over the range $[0,20]$, where higher is better.\n- Feasibility: monthly out-of-pocket cost in dollars, given as $900$ for Drug $A$ and $450$ for Drug $B$. Normalize linearly on $[0,1]$ over the range $[200,1200]$, where lower is better.\n\nStakeholder weighting reflects that efficacy receives adjustable emphasis $w_{E} \\in [0,1]$, while the remaining three criteria maintain fixed ratios $w_{S}:w_{Q}:w_{F} = 2:1:1$ (Safety:Quality of Life:Feasibility) and must together sum to $1 - w_{E}$, consistent with nonnegativity and normalization. Use a linear additive value model consistent with MCDA and these normalizations to compute the global value of each drug as a function of $w_{E}$.\n\nPerform a sensitivity analysis on $w_{E}$ by finding the exact value of $w_{E}$ at which the two drugs have equal global value. Express your final answer as a single simplified fraction with no units; do not round.",
            "solution": "**Problem Validation**\n\n**Step 1: Extract Givens**\n- Decision framework: Multi-Criteria Decision Analysis (MCDA) using a linear additive value model.\n- Model form: Aggregation of normalized criterion-specific values under a linear additive model with nonnegative weights that sum to $1$.\n- Normalization: Linear transformations mapping raw criterion measures to $[0,1]$, where $1$ is most preferred and $0$ is least preferred.\n- Alternatives: Drug $A$, Drug $B$.\n- Criteria: Efficacy ($E$), Safety ($S$), Quality of Life ($Q$), Feasibility ($F$).\n- Raw Data (Drug $A$):\n  - Efficacy: $0.18$ (absolute response rate increase).\n  - Safety: $0.17$ (proportion of Grade $3$-$4$ adverse events).\n  - QoL: $12$ points (improvement on a $0$-$100$ scale).\n  - Feasibility: $900$ dollars (monthly out-of-pocket cost).\n- Raw Data (Drug $B$):\n  - Efficacy: $0.11$.\n  - Safety: $0.10$.\n  - QoL: $8$ points.\n  - Feasibility: $450$ dollars.\n- Normalization Rules:\n  - Efficacy: Linear on $[0, 0.35]$, higher is better.\n  - Safety: Linear on $[0.05, 0.25]$, lower is better.\n  - QoL: Linear on $[0, 20]$, higher is better.\n  - Feasibility: Linear on $[200, 1200]$, lower is better.\n- Weighting Scheme:\n  - Efficacy weight: $w_{E} \\in [0,1]$.\n  - Other weights sum: $w_{S} + w_{Q} + w_{F} = 1 - w_{E}$.\n  - Weight ratios: $w_{S}:w_{Q}:w_{F} = 2:1:1$.\n- Task: Find the exact value of $w_{E}$ where the global values of Drug $A$ and Drug $B$ are equal.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem uses MCDA, a standard and well-established methodology in decision analysis, applied to a realistic clinical pharmacology scenario. The criteria, metrics, and data ranges are plausible. The model is a standard linear additive value function. The problem is scientifically sound.\n- **Well-Posed:** The problem provides all necessary data and defines all functions (normalization, aggregation) required to construct a solvable system. It requests a unique value (the indifference point), which is expected from a system of two linear equations.\n- **Objective:** The problem is stated in precise, quantitative, and unbiased language. All inputs are numerical, and the methodology is explicitly defined.\n- **Incomplete or Contradictory Setup:** The problem is self-contained. All constraints, data, and definitions are provided and are mutually consistent.\n- **Unrealistic or Infeasible:** The data and ranges are clinically plausible for the described context.\n- **Ill-Posed or Poorly Structured:** The problem structure is clear and leads to a unique, meaningful solution.\n\n**Step 3: Verdict and Action**\nThe problem is scientifically grounded, well-posed, objective, and self-contained. Therefore, it is deemed valid. A solution will be provided.\n\n**Solution**\nThe task is to find the efficacy weight, $w_{E}$, at which the global values of Drug $A$ and Drug $B$ are equal. The global value $V$ for each drug is the weighted sum of its normalized scores across the four criteria: Efficacy ($E$), Safety ($S$), Quality of Life ($Q$), and Feasibility ($F$).\n\nThe global value model is given by:\n$$V = w_E v_E + w_S v_S + w_Q v_Q + w_F v_F$$\nwhere $v_i$ is the normalized value for criterion $i$ and $w_i$ is its corresponding weight.\n\n**1. Normalization of Raw Scores**\nThe raw data must be converted to normalized values on a scale from $0$ to $1$.\nFor a criterion where a higher score is better over a range $[x_{\\min}, x_{\\max}]$, the normalization function for a raw score $x$ is:\n$$v(x) = \\frac{x - x_{\\min}}{x_{\\max} - x_{\\min}}$$\nFor a criterion where a lower score is better, the function is:\n$$v(x) = \\frac{x_{\\max} - x}{x_{\\max} - x_{\\min}}$$\nWe apply these functions to the given data.\n\n- **Efficacy (E)**: Higher is better. Range $[0, 0.35]$.\n  - Drug $A$: $v_{E,A} = \\frac{0.18 - 0}{0.35 - 0} = \\frac{0.18}{0.35} = \\frac{18}{35}$.\n  - Drug $B$: $v_{E,B} = \\frac{0.11 - 0}{0.35 - 0} = \\frac{0.11}{0.35} = \\frac{11}{35}$.\n\n- **Safety (S)**: Lower is better. Range $[0.05, 0.25]$.\n  - Drug $A$: $v_{S,A} = \\frac{0.25 - 0.17}{0.25 - 0.05} = \\frac{0.08}{0.20} = \\frac{8}{20} = \\frac{2}{5}$.\n  - Drug $B$: $v_{S,B} = \\frac{0.25 - 0.10}{0.25 - 0.05} = \\frac{0.15}{0.20} = \\frac{15}{20} = \\frac{3}{4}$.\n\n- **Quality of Life (Q)**: Higher is better. Range $[0, 20]$.\n  - Drug $A$: $v_{Q,A} = \\frac{12 - 0}{20 - 0} = \\frac{12}{20} = \\frac{3}{5}$.\n  - Drug $B$: $v_{Q,B} = \\frac{8 - 0}{20 - 0} = \\frac{8}{20} = \\frac{2}{5}$.\n\n- **Feasibility (F)**: Lower is better. Range $[200, 1200]$.\n  - Drug $A$: $v_{F,A} = \\frac{1200 - 900}{1200 - 200} = \\frac{300}{1000} = \\frac{3}{10}$.\n  - Drug $B$: $v_{F,B} = \\frac{1200 - 450}{1200 - 200} = \\frac{750}{1000} = \\frac{75}{100} = \\frac{3}{4}$.\n\n**2. Determination of Criterion Weights**\nThe efficacy weight is $w_E$. The remaining weights sum to $1 - w_E$, with the ratio $w_S:w_Q:w_F = 2:1:1$. Let $w_Q = w_F = k$, which implies $w_S = 2k$.\nThe sum is $w_S + w_Q + w_F = 2k + k + k = 4k$.\nWe have $4k = 1 - w_E$, so $k = \\frac{1 - w_E}{4}$.\nThe individual weights are:\n$$w_S = 2k = \\frac{2(1 - w_E)}{4} = \\frac{1 - w_E}{2}$$\n$$w_Q = k = \\frac{1 - w_E}{4}$$\n$$w_F = k = \\frac{1 - w_E}{4}$$\n\n**3. Global Value Equations and Sensitivity Analysis**\nThe global value for Drug $A$ ($V_A$) and Drug $B$ ($V_B$) can be expressed as functions of $w_E$:\n$$V_A(w_E) = w_E v_{E,A} + (1 - w_E)\\left(\\frac{v_{S,A}}{2} + \\frac{v_{Q,A}}{4} + \\frac{v_{F,A}}{4}\\right)$$\n$$V_B(w_E) = w_E v_{E,B} + (1 - w_E)\\left(\\frac{v_{S,B}}{2} + \\frac{v_{Q,B}}{4} + \\frac{v_{F,B}}{4}\\right)$$\nWe define aggregated non-efficacy scores, $C_A$ and $C_B$, for convenience:\n$$C_A = \\frac{v_{S,A}}{2} + \\frac{v_{Q,A}}{4} + \\frac{v_{F,A}}{4} = \\frac{1}{2}\\left(\\frac{2}{5}\\right) + \\frac{1}{4}\\left(\\frac{3}{5}\\right) + \\frac{1}{4}\\left(\\frac{3}{10}\\right) = \\frac{1}{5} + \\frac{3}{20} + \\frac{3}{40}$$\nUsing a common denominator of $40$:\n$$C_A = \\frac{8}{40} + \\frac{6}{40} + \\frac{3}{40} = \\frac{17}{40}$$\n$$C_B = \\frac{v_{S,B}}{2} + \\frac{v_{Q,B}}{4} + \\frac{v_{F,B}}{4} = \\frac{1}{2}\\left(\\frac{3}{4}\\right) + \\frac{1}{4}\\left(\\frac{2}{5}\\right) + \\frac{1}{4}\\left(\\frac{3}{4}\\right) = \\frac{3}{8} + \\frac{2}{20} + \\frac{3}{16} = \\frac{3}{8} + \\frac{1}{10} + \\frac{3}{16}$$\nUsing a common denominator of $80$:\n$$C_B = \\frac{30}{80} + \\frac{8}{80} + \\frac{15}{80} = \\frac{53}{80}$$\nThe condition for equal global value is $V_A(w_E) = V_B(w_E)$:\n$$w_E v_{E,A} + (1 - w_E)C_A = w_E v_{E,B} + (1 - w_E)C_B$$\nRearranging to solve for $w_E$:\n$$w_E v_{E,A} - w_E v_{E,B} = (1 - w_E)C_B - (1 - w_E)C_A$$\n$$w_E (v_{E,A} - v_{E,B}) = (1 - w_E)(C_B - C_A)$$\n$$w_E (v_{E,A} - v_{E,B}) = C_B - C_A - w_E(C_B - C_A)$$\n$$w_E [(v_{E,A} - v_{E,B}) + (C_B - C_A)] = C_B - C_A$$\n$$w_E = \\frac{C_B - C_A}{(v_{E,A} - v_{E,B}) + (C_B - C_A)}$$\nWe calculate the necessary differences:\n$$v_{E,A} - v_{E,B} = \\frac{18}{35} - \\frac{11}{35} = \\frac{7}{35} = \\frac{1}{5}$$\n$$C_B - C_A = \\frac{53}{80} - \\frac{17}{40} = \\frac{53}{80} - \\frac{34}{80} = \\frac{19}{80}$$\nSubstituting these values into the expression for $w_E$:\n$$w_E = \\frac{\\frac{19}{80}}{\\frac{1}{5} + \\frac{19}{80}}$$\nTo add the terms in the denominator, we use a common denominator of $80$:\n$$w_E = \\frac{\\frac{19}{80}}{\\frac{16}{80} + \\frac{19}{80}} = \\frac{\\frac{19}{80}}{\\frac{35}{80}}$$\n$$w_E = \\frac{19}{35}$$\nThis fraction is simplified and lies within the valid range for $w_E$, i.e., $[0, 1]$.",
            "answer": "$$\\boxed{\\frac{19}{35}}$$"
        }
    ]
}